NCT06488105 - Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

March 31, 2029

Conditions

Lipid DisorderHypercholesterolemiaCardiovascular DiseasesAtherosclerosis

Interventions

DRUG

Statin (rosuvastatin 10 or 40 mg daily, depending on risk)

moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)

BEHAVIORAL

Healthy Lifestyle Counseling

Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework

OTHER

Outpatient Followup

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral

Trial Locations (1)

27517

RECRUITING

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Wake Forest University Health Sciences

OTHER